NCT06437210View on ClinicalTrials.gov

Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

December 15, 2023

Study Completion Date

March 15, 2024

Conditions
Post-COVID-19 SyndromeCOVID-19DyspneaFatigueCoughInflammation
Interventions
DIETARY_SUPPLEMENT

Viusid Oral Solution

Patients in the experimental intervention group will be administered Viusid Oral Solution (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.

DIETARY_SUPPLEMENT

Placebo

Patients in the experimental intervention group will be administered Placebo (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.

Trial Locations (1)

110131

Fundación CR INVESTIGATION INSTITUTE, Bogotá

All Listed Sponsors
lead

Catalysis SL

INDUSTRY